TScan Therapeutics, Inc. - 8-K Filing
TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA™ Phase 1 study evaluating TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation. Of the 14 patients who received their first infusion, 11 achieved complete donor chimerism within ~3 weeks and two more were approaching it; one patient remained in complete chimerism for six months post-transplant. The company reported a ~90% manufacturing success rate using its commercial-ready process and plans to begin the Phase 3 ALLOHA-2™ study this month. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $TCRX